Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting
Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of ...
Healio7d
‘There is a whole other world out there’: Beyond CAR-T therapies for autoimmune diseases
Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
Medindia6d
New Biomarkers Predict ICANS Risk in CAR-T Cell Therapy
Discover the newly identified proteins to predict ICANS, improving the safety of CAR-T cell therapy by identifying high-risk ...
Targeted Oncology3d
BMT CTN 1902 in Myeloma: Key Findings With Garfall
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...
eLife2d
Expression of a single inhibitory member of the Ly49 receptor family is sufficient to license NK cells for effector functions
A novel mouse model offers definitive evidence that a single inhibitory receptor family governs the critical natural killer cell functions of licensing and missing-self.
Healio6d
Siltuximab reduces severity of cytokine release syndrome, ICANS after CAR T-cell therapy
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...